Penn Capital Management’s Cardlytics CDLX Stock Holding History

Penn Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-26,350	Closed	-$6.85M	–	218
2019 Q2	$6.85M	Buy	26,350 +7,289	+38%	+$1.46M	0.68%	54
2019 Q1	$3.15M	Buy	19,061 +3,683	+24%	+$599K	0.31%	108
2018 Q4	$1.67M	Buy	+15,378	New	+$2.59M	0.17%	156
2018 Q2	–	Sell	-4,754	Closed	-$695K	–	270
2018 Q1	$695K	Buy	+4,754	New	+$804K	0.05%	223

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Penn Capital Management's CDLX Position: Q2 2021 in Review

Penn Capital Management sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 4,048 shares — an estimated $4.44M sold.

Penn Capital Management first reported a position in CDLX in Q3 2019 and held it in 7 quarters. The position peaked at $6.91M in Q3 2019. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

Penn Capital Management reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
Penn Capital Management sold 4,048 Cardlytics shares in Q2 2021, an estimated $4.44M.
Penn Capital Management first reported a position in Cardlytics in Q3 2019 and held it in 7 quarters.
Penn Capital Management's Cardlytics position peaked at $6.91M in Q3 2019.
189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Penn Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.